Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.
Saved in:
| Title: | Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71. |
|---|---|
| Authors: | Small AM; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States., Patel SM; TIMI Study Group, Boston, Massachusetts, United States., Giugliano RP; Harvard Medical School, Boston, United States., Morrow DA; TIMI Study Group, Boston, Massachusetts, United States., Goodrich EL; TIMI Study Group, Boston, Massachusetts, United States., Hug B; Anthos Therapeutics, Cambridge, Massachusetts, United States., Parkar S; Anthos Therapeutics, Cambridge, Massachusetts, United States., Chen SA; Taipei Veterans General Hospital, Taipei, Taiwan., Goodman SG; St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada., Joung B; Yonsei University, Seoul, Korea, Republic of., Kiss RG; Semmelweis University Heart and Vascular Center, Budapest, Hungary., Wojakowski W; Medical University of Silesia, Katowice, Poland., Weitz JI; McMaster University, Hamilton, Ontario, Canada., Bloomfield D; Anthos Therapeutics, Cambridge, Massachusetts, United States., Sabatine MS; TIMI Study Group, Boston, Massachusetts, United States., Ruff CT; TIMI Study Group, Boston, Massachusetts, United States. |
| Source: | Blood [Blood] 2026 May 29. Date of Electronic Publication: 2026 May 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
